Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Non-Current Liabilities: 2022-2024

Historic Total Non-Current Liabilities for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to $2.5 million.

  • Stoke Therapeutics' Total Non-Current Liabilities fell 8.02% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year decrease of 8.02%. This contributed to the annual value of $2.5 million for FY2024, which is 93.47% down from last year.
  • According to the latest figures from FY2024, Stoke Therapeutics' Total Non-Current Liabilities is $2.5 million, which was down 93.47% from $38.0 million recorded in FY2023.
  • In the past 5 years, Stoke Therapeutics' Total Non-Current Liabilities ranged from a high of $39.8 million in FY2022 and a low of $2.5 million during FY2024.
  • For the 3-year period, Stoke Therapeutics' Total Non-Current Liabilities averaged around $26.8 million, with its median value being $38.0 million (2023).
  • Data for Stoke Therapeutics' Total Non-Current Liabilities shows a maximum YoY plummeted of 93.47% (in 2024) over the last 5 years.
  • Over the past 3 years, Stoke Therapeutics' Total Non-Current Liabilities (Yearly) stood at $39.8 million in 2022, then dropped by 4.69% to $38.0 million in 2023, then crashed by 93.47% to $2.5 million in 2024.